Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Sunshine Biopharma (SBFM) over the last 10 years, with Q3 2025 value amounting to 0.26%.

  • Sunshine Biopharma's Return on Capital Employed fell 600.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.26% for FY2024, which is 500.0% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Return on Capital Employed of 0.26% as of Q3 2025, which was down 600.0% from 0.26% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Return on Capital Employed ranged from a high of 0.1% in Q3 2022 and a low of 3.09% during Q1 2021
  • In the last 5 years, Sunshine Biopharma's Return on Capital Employed had a median value of 0.26% in 2025 and averaged 0.75%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -39000bps in 2021, then skyrocketed by 27800bps in 2022.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Return on Capital Employed stood at 1.08% in 2021, then increased by 11bps to 0.96% in 2022, then skyrocketed by 77bps to 0.22% in 2023, then dropped by -10bps to 0.24% in 2024, then dropped by -8bps to 0.26% in 2025.
  • Its last three reported values are 0.26% in Q3 2025, 0.26% for Q2 2025, and 0.24% during Q1 2025.